Our team of experts brings you cancer-related news and research updates.
According to a new study, death rates from non-small cell lung cancer have fallen sharply in recent years, mostly due to advances in treatment.
The US Food and Drug Administration (FDA) has approved the immunotherapy drug Tecentriq (atezolizumab) for the treatment of small cell lung cancer (SCLC).
The US Food and Drug Administration had approved the immunotherapy drug Opdivo (nivolumab) to treat people with small cell lung cancer (SCLC).